BACKGROUND: Most reviews of IVF ovarian stimulation protocols have insufficiently accounted for various patient populations, such as ovulatory women, women with polycystic ovary syndrome (PCOS) or women with poor ovarian response, and have included studies in which the agonist or antagonist was not the only variable between the compared study arms.
OBJECTIVE AND RATIONALE:
The aim of the current study was to compare GnRH antagonist protocols versus standard long agonist protocols in couples undergoing IVF or ICSI, while accounting for various patient populations and treatment schedules.
SEARCH METHODS:
The Cochrane Menstrual Disorders and Subfertility Review Group specialized register of controlled trials and Pubmed and Embase databases were searched from inception until June 2016. Eligible trials were those that compared GnRH antagonist protocols and standard long GnRH agonist protocols in couples undergoing IVF or ICSI. The primary outcome was ongoing pregnancy rate. Secondary outcomes were: live birth rate, clinical pregnancy rate, number of oocytes retrieved and safety with regard to ovarian hyperstimulation syndrome (OHSS). Separate comparisons were performed for the general IVF population, women with PCOS and women with poor ovarian response. Pre-planned subgroup analyses were performed for various antagonist treatment schedules.
OUTCOMES:
We included 50 studies. Of these, 34 studies reported on general IVF patients, 10 studies reported on PCOS patients and 6 studies reported on poor responders. In general IVF patients, ongoing pregnancy rate was significantly lower in the antagonist group
Introduction
An essential part of ovarian stimulation in IVF/ICSI involves comedication to prevent premature luteinization. The two approaches for this are pituitary desensitization with prolonged daily administration of a gonadotrophin releasing hormone (GnRH) agonist or an instant blockade of the pituitary luteinizing hormone (LH) secretion with a GnRH antagonist (Huirne and Lambalk, 2001; Huirne et al., 2004a,b) . Both procedures are effective in blocking premature LH surges (The ganirelix dose-finding group, 1998; Janssens et al., 2000; Huirne et al., 2004a,b) . Advantages of antagonists are the shorter duration of the analog treatment, the shorter duration of stimulation with FSH and the lower risk of developing ovarian hyperstimulation syndrome (OHSS) (Al-Inany et al., 2016) . One particular advantage in the context of preventing OHSS may be the possiblity of triggering ovulation with a short endogenous LH surge induced with a GnRH agonist instead of the prolonged exogenous LH action induced by the administration of hCG (Youssef et al., 2014) . In addition, with the standard 'long agonist protocol' approximately 25 daily subcutaneous injections are needed, whereas antagonists require around 5 daily subcutaneous injections. A number of systematic reviews have appeared over the past decade Al-Inany et al., 2007 Xiao et al., 2014) . The most recent review indicates that overall GnRH antagonists do not compromise effectiveness and significanly prevent OHSS (Al-Inany et al., 2016) .
Most reviews have insufficiently accounted for various patient populations, such as ovulatory women, women with polycystic ovary syndrome (PCOS) or women with poor ovarian response. This is likely to be of relevance since these women strongly differ with regard to ovarian responsiveness particularly in relation to the long agonist and antagonist protocols (Huirne et al. 2007 ). All of the previous reviews have included a number of studies in which the agonist or antagonist was not the only variable between the compared study arms and, by doing so, analysis of the specific effect of the type of analog used is not feasible. In some studies, the applied FSH dose was lower in the antagonist arm in comparison to the agonist regimen, which could affect oocyte yield, pregnancy rate and OHSS (Serafini et al., 2006; Baart et al., 2007; Heijnen et al., 2007) . In other studies, there were differences in stimulation strategies between the study arms which could serve as uncontrolled confounders (Kiochi et al., 2006; Lin et al., 2006; Engman et al., 2008a; Karamzadeh et al., 2010; Di Luigi et al., 2011; Revelli et al., 2014) (Table II) .
An important matter with regard to application of the GnRH antagonist is the inability to plan the start of an IVF treatment. Therefore many clinics apply some sort of sex-hormonal pretreatment in order to program the start of stimulation. This is a widely spread approach when antagonists are applied and it occurs prior to start of stimulation. Because of this universally wide spread application and the need to examine actual clinical practice, we decided to include the 22 studies that applied this strategy.
Thus we conducted a systematic review and meta-analysis evaluating the effect of the type of GnRH analog used in IVF to prevent the premature LH surge, with regard to pregnancy outcomes and OHSS rates, with special attention to differences in patient populations and interventions.
Materials and Methods

Search, identification and selection of studies
Only published randomized controlled studies (RCTs) were included in this review. Reported quasi randomized trials were not included. The patient populations consisted of all women undergoing IVF/ICSI with ovarian stimulation. We compared a standard long GnRH agonist protocol versus various flexible and fixed protocols of GnRH antagonists with or without oral hormonal programming (OHP) pretreatment. The primary outcome was ongoing pregnancy rate. Secondary outcomes were live birth rate, clinical pregnancy rate, number of oocytes retrieved and safety outcome (with regard to OHSS).
The Cochrane Menstrual Disorders and Subfertility Review Group specialized register of controlled trials and Pubmed and Embase databases were searched from inception in 1996 through June 2016 using the following search terms: gonadorelin agonist, gonadorelin antagonist, infertility therapy, buserelin, triptorelin, goserelin, leuprorelin, nafarelin, cetrorelix, ganirelix and teverelix. Abstracts of relevant meetings of the European Society of Human Reproduction and Embryology, The American Society of Reproductive Medicine, the World Congresses on Controversies in Obstetrics, Gynecology & Infertility and the World Congresses on Human Reproduction, all from the year 1996, which was just after completion and reporting of the first formal phase III studies that compared the long protocol agonist with the antagonist, were searched. We excluded studies that compared more than one variable, for instance studies that, in addition to comparing a GnRH antagonist with a GnRH agonist, also compared agonist versus hCG triggering and studies in which not only the type of analog for prevention of premature luteinization but also dosage or type of gonadotrophins varied between compared groups.
We assessed all eligible studies for appropriateness for inclusion and methodological quality. Methodological criteria were trial characteristics, population characteristics, interventions and outcomes. Study selection was performed independently by two reviewers (F.R.B. and J.A.H.) . Authors of trials were contacted to request additional information if the papers contained insufficient information. We received replies from 15 of the 43 authors we contacted.
The primary outcome was ongoing pregnancy defined as an intact pregnancy at 12 weeks of amenorrhea. Secondary outcomes were OHSS per woman randomized, live birth, clinical pregnancy, defined as intrauterine pregnancy with a positive heartbeat at 6 weeks of gestation, and number of oocytes retrieved.
Statistical analysis
We performed the meta-analysis according to the intention-to-treat (ITT) principle. Pregnancy outcomes, Relative Risk (RR) with 95% confidence intervals (CI) were calculated and combined for meta-analysis with Review Manager (RevMan) software using the random effect model. For number of oocytes, we calculated the weighted mean difference (WMD) with 95% CI. Heterogeneity between the results of different studies was determined using the inconsistency measure I 2 (Higgins et al., 2011) . The absolute risk reduction was calculated by subtracting event rates in the antagonist group from We performed separate analyses for three populations: the general IVF population, women with PCOS and women with poor ovarian response. An IVF patient was categorized as belonging to the general IVF population, if reported as being ovulatory or with a regular menstrual cycle or when not specified. Women with PCOS and women with poor response were considered as such when categorized in the relevant publication accordingly. A pre-planned subgroup analysis was performed based on the type of antagonist protocol used, i.e. a flexible protocol without OHP pretreatment, a fixed protocol without OHP, a flexible protocol with OHP, and a fixed protocol with OHP. We assessed the likelihood of publication bias by constructing a funnel plot (Higgins et al., 2011) and we used Egger's test to detect asymmetry.
Results
In total, 607 studies were retrieved. After checking for relevance of the comparisons and the truly randomized nature of the trials, 50 randomized RCTs were included in the systematic review (Fig. 1) . The characteristics of all 50 included RCTs are summarized in Table I . The excluded studies are shown in Table II . The included studies randomized a total of 9950 women. We subdivided these women into three subcategories: women belonging to the general IVF population (34 studies), women with PCOS (10 studies) and women with poor ovarian response (6 studies).
In the general IVF population, from 21 studies using a flexible protocol, six were pretreated with OHP and from the 13 studies with a fixed protocol, four were pretreated with OHP.
In PCOS patients, seven trials used the flexible protocol and three used the fixed protocol. All of these trials applied OHP pretreatment. Of the poor responder population, three studies used a flexible protocol, one study combined the flexible protocol with OHP and two studies used the fixed protocol and OHP.
Types of antagonist used were cetrorelix (32 studies), ganirelix (15 studies), one did not report type of antagonist and in two studies both cetrorelix or ganirelix were used. Types of agonist used were buserelin (17 studies), leuprorelin (12 studies), triptrorelin (16 studies) and nafarelin (5 studies). All studies used a long multiple dose (MD) agonist protocol (50 studies). The day of start with FSH stimulation varied from OHP stop + 1 to 5 days or cycle days 2 to 5. The gonadotropin starting dose varied from 150 to 450 IU of recombinant follicle stimulating hormone (rFSH) or human menopausal gonadotropin (hMG). All of the included trials had a parallel study design. Studies were multicentre (11 studies) or single center (38 studies) and in one case, it was unclear. Inclusion and exclusion criteria were available in all studies, but differently specified especially in the 34 studies with a general IVF population. Of these studies, 19 described a required regular menstrual cycle in the inclusion criteria, four studies described the exclusion of PCOS and three described exclusion of endocrine disorders, while eight studies did not adequately specify menstrual cycle regularity. The method of randomization was computerized in 28 studies; an interactive voice response was used in four studies; five studies used sealed envelopes without further details regarding the randomization method; number tables were used in threee studies; a randomization list sequentially numbered and a centralized telephone was used in three studies and the method of randomization was not available in seven studies. Allocation concealment was adequate in 32 studies, not concealed in one and unclear in 17 studies. The randomization ratio was: 1:1 (38 studies), 2:1 (5 studies), 1:1:1 (6 studies), or unclear (1 study). The duration of the studies varied from three months to five years and two months and was not available for 11 studies. ITT analysis was performed in 17 studies, not performed in 26 studies, inadequate in six studies and unclear in one study. Financial support was declared in 25 studies and none was declared in 25 studies. The funnel plot demonstrated some asymmetry although, overall, the Egger's test was not significant (P = 0.08) (Fig. 2) . There seemed to be no significant asymmetry for the general population and the population with PCOS (Egger's test P = 0.87 and P = 0.09, respectively), but for the poor responder population, the asymmetry was most profound, thus suggesting publication bias (Egger's test P = 0.01) (Fig. 2) .
General IVF population
There were 26 trials, entailing 7191 couples from a general IVF population, that provided the primary outcome of ongoing pregnancy (Fig. 3) . In these couples, the ongoing pregnancy rate was significantly lower after the use of antagonists than after the long agonist protocol (RR 0.89, 95% CI 0.82-0.96. I 2 = 0%). The ongoing pregnancy rate after antagonist use was 23.8% compared to 27.4% after the use of agonists, with an absolute difference of 3.6%. Ongoing pregnancy rates in the general population per prespecified antagonist treatment protocol are summarized in Fig. 4 . Ongoing pregnancy rates were lower when a flexible antagonist protocol was used with OHP (5 trials, 625 couples; RR 0.74, 95% CI 0.59-0.91. I 2 = 0%). The RR was 0.84, 95% CI 0.71-1.00 I 2 = 0% for a flexible protocol without OHP (10 trials, 1976 couples). There was no evidence of a difference in ongoing pregnancy rate between antagonist and agonist when a fixed antagonist protocol was used without OHP (9 trials, 3327 couples; RR 0.94, 95% CI 0.83-1.05. I 2 = 0%). A fixed protocol with OHP pretreatment also did not yield a significant difference (3 trials, 1263 couples; RR 0.94, 95% CI 0.79-1.12. I 2 = 0%).
In the general population clinical pregnancy rate was lower with antagonist (34 trials, 8084 couples; RR 0.90, 95% CI 0.84-0.96. I 2 = 0%) (Fig. 5 ). In the general population the RR for live birth with use of antagonist was 0.91 (CI 0.79-1.04) with 10 trials and 1590 patients (Fig. 8) . Furthermore in this general IVF population, the agonist protocol yielded significantly more oocytes (31 trials, 7080 couples; WMD −1.04, CI −1.56 to −0.52. I 2 = 81%) (Fig. 6 ). Due to the high statistical heterogeneity, this finding should be considered with care. Antagonist treatment in this general population resulted in a significantly lower OHSS rate than agonist (22 trials, 5598 couples; RR 0.63, CI 0.50-0.81. I 2 = 0) (Fig. 7) . Compared to a control OHSS rate of 6.2% following the agonist protocol, the the development of OHSS following the antagonist protocol would be at a rate of 3.7%, with an absolute risk difference of 2.5%.
Women with PCOS
Nine trials including 1294 couples from a PCOS population provided the primary outcome of ongoing pregnancy. No evidence of a difference in ongoing pregnancy rate was found in women with PCOS (RR 0.97, 95% CI 0.84-1.11. 0%) for the antagonist versus agonist groups (Fig. 3) . When subgrouping the antagonist protocol, no evidence for a difference was found for antagonist versus agonist, either when a fixed protocol after OHP pretreatment was used (3 trials, 434 couples; RR 0.94, 95% CI 0.63 -1.40. I 2 = 0%) or when a flexible protocol after OHP pretreatment was used (7 trials, 814 couples; RR 1.02, 95% CI 0.79-1.36. I 2 = 0%).
In the PCOS patients, the RR for live birth with the use of antagonist was 0.90 (CI 0.69-1.19) compared to agonist, in 3 trials and 363 patients (Fig. 8) . There was also no difference in clinical pregnancy rate between antagonist and a long agonist protocol (10 trials, 1086 couples; RR 1.01, 95% CI 0.86-1.19) (Fig. 5 ). There were no differences in oocyte yield (Fig. 6) .
The OHSS rate was significantly lower when antagonist was used instead of agonist (RR 0.53, (Fig. 7) .
Women with poor ovarian response
Six trials including 780 couples from a poor responder population provided the primary outcome of ongoing pregnancy (Fig. 3) . No evidence of a difference in ongoing pregnancy rate was found in poor responders (RR 0.87, 95% CI 0.65-1.17) for antagonist versus agonist (Fig. 3) . In view of the low number of trials, no further subgrouping of the antagonist protocol group was done.
In the poor response patients, the RR for live birth with use of antagonist compared to agonist was 0.89 (CI 0.56-1.41) from 3 trials and 544 patients (Fig. 8) . There was also no evidence of a difference in clinical pregnancy rate (6 trials, 780 couples; RR 0.85, 95% CI 0.66-1.10) (Fig. 5 ). There were no differences in oocyte yield (Fig. 6) .
None of the six trials had data on OHSS.
Sensitivity analysis
Sensitivity analysis on the primary endpoint, namely ongoing pregnancy, leaving out studies not reporting mode of randomization and studies that used steroid programming by oral hormonal treatment (OHP) in the general population, the RR for ongoing pregnancy rate was not changed at 0.89 with a 95% CI of 0.80-0.99 in favor of the agonist. Leaving out one such study in the poor responder group resulted in a slightly lower RR of 0.85 with a CI of 0.64-1.13 for ongoing pregnancy rate.
Discussion
This meta-analysis showed that with regard to the chance of an ongoing pregnancy in general IVF patients, when evident ovarian dysfunction such as PCOS or poor response are excluded explicitly, there is an absolute risk reduction of 3.6% in ongoing pregnancy rates when a GnRH antagonist, rather than an agonist, protocol was used for prevention of premature luteinization. The number needed to harm was 28, i.e. for every 28 women treated with antagonist one less ongoing pregnancy would occur. On the other hand, use of antagonist instead of agonist reduced the absolute rate of OHSS by 2.5%, with a number of women needed to prevent one case of OHSS being 40. Subanalyses suggest that the use of a fixed protocol may at least partly resolve the difference in clinical effectiveness with GnRH antagonist. Based on its 3.6% superiority in terms of ongoing pregnancy rates, one could argue that the long GnRH agonist protocol should be the first choice treatment at cost of a 2.5% increase of chance of the relatively rare but potentially dangerous OHSS.
It should be noted that a recent study employing a so-called discrete choice analysis evaluating patients preferences, the respondents were willing to trade-off 0.87 effectiveness with a decrease in OHSS risk (van den Wijngaard et al., 2014) . The trade-off questions in that study showed that even at a 2% increase in pregnancy rate in favor of the agonists, the majority of the respondents changed their preference from antagonists to agonists.
In couples with PCOS, we found no evidence for a difference in ongoing pregnancy or clinical pregnancy rate, but again there was a significantly lower OHSS rate in the antagonist group. In PCOS patients, the number needed to prevent one case of OHSS was 14 (95% CI 7 -50) treatments with antagonist.
In poor responders, we also found no statistical differences with regard to pregnancy rates although the power seems too low to make solid statements for this group. There was no data on OHSS, probably because OHSS is rare in this population.
Subgroup analysis based on type of use of antagonist with or without steroid hormone pretreatment for programming showed that only the combination of a flexible antagonist application after hormonal programming yielded statistical significance in favor of agonist use. So possibly each of the other three strategies may individually not be inferior to the long protocol agonist use although the effect sizes varying from 0.84 to 0.94 systematically do point into that direction.
The particular strengths of this review are that it has accounted in an integral way as much as possible for the type of patient, type of antagonist application and presence of collateral stimulation variables as potential important factors. By doing so, we obtained a clearer view of an effect of the intervention under scrutiny namely GnRH antagonist versus agonist.
Our analysis also has some shortcomings. We could not entirely exclude the possibility that in several studies that we assigned to the general population, certain ovulatory and even anovulatory PCOS patients and poor responders were present. However, our finding that the ongoing pregnancy rate was lower in the general (thus to some extent unspecified) IVF population would likely to be strengthened potentially if those patients, who actually may have no lower pregnancy rate when analyzed specifically, could have been excluded too.
There was some indication of publication bias, specifically in the poor responders group. The three smallest studies were in favor of the agonist although the confidence intervals of the effect estimates for all studies overlapped. For the general population, there was no indication of publication bias. Publication bias may to some extent have been a consequence of our a priori choice to only select published studies.
Although we explicitly focused on comparisons between use of OHP or not and fixed and flexible protocols in various patient groups, we did not compare OHP plus antagonist and antagonist alone or with agonist versus agonist alone since this has been addressed elsewhere (Smulders et al., 2010) .
We focused on ongoing pregnancy as the primary outcome for these analyses as live birth rates were often not available. Live birth is very important and often rightfully selected as primary endpoint. We decided not to do so in this study because at the time and still today reviews on this subject invariably show a tremendous quantitative discrepancy between data reporting on live birth and ongoing pregnancy, where often the ongoing pregnancy rate has sufficient power signals differences whereas the live birth rate has adue to lack of power. Since live birth rate has been taken as the primary endpoint in more recent reviews, the key message of such studies also consequently ends with the reassuring 'there are no statistical differences in live birth rate'. Therefore because ongoing pregnancy is an extremely good proxy for live birth rate (Braakhekke et al., 2014) and almost all published studies report ongoing pregnancy, we still felt confident with the primary endpoint we originally chose for the aforementioned reasons. We should not ignore the wealth of information that comes from massive ongoing pregnancy data against limited available data on live birth despite its preferred outcome status.
Despite this, the numbers of PCOS patients and poor responders remained low.
OHSS was an important outcome but OHSS was poorly defined by various studies and it was not a primary endpoint in most studies analyzed. It should be noted that the rare but still greater prevalence of OHSS with use of an agonist is not caused by the agonist itself but by hyperresponse of the ovary to the FSH stimulation and by the subsequent use of hCG for ovulation triggering. The lower ongoing pregnancy rates observed with the use of a GnRH antagonist for the prevention of premature LH surges in the general IVF population, may be explained in several ways. First, the LH surges may not be adequately suppressed. A recently published overview showed that in the original straightforward phase III studies that compared antagonists with agonists, LH surges occurred in over 8% of the fixed start antagonist cycles compared to less than 1% with the long protocol agonists (Kolibianakis et al., 2011) . Around 80% of these surges occurred before the start of the antagonist treatment. This indicates that the start of the antagonist on FSH stimulation day 6 for prevention of LH surges is likely to be too late. The same is probably true for the so-called flexible start of the antagonists based on a follicle diameter of 14 mm, since this is usually later than day 6 of simulation and may therefore result in an even higher rate of LH surges (Devroey et al., 2004; Al-Inany et al., 2005; Tarlatzis et al., 2006) . Second, oocyte yield has been reported to be lower with the GnRH antagonists and given the established relation between oocyte yield and successful pregnancy, the lower pregnancy rates found with antagonists could be attributed to this (Nelson et al., 2007) One reason for lower oocyte yield may be a more asynchronous development of follicles due to endogenous FSH secretion in the early follicular phase, while suppression of FSH during prolonged agonist treatment may result in more synchronous development without large 'forerunners' that make administration of hCG and ending of stimulation mandatory, thereby allowing extension of the length of the period of exposure of exogenous FSH (Huirne et al., 2007) .
The use of antagonist may present an endocrinologically unfavorable scenario: in the early stage of the cycle, there may beinsufficient suppression of endogenous pituitary gonadotrophin secretion leading to premature LH surges and advanced follicular development with both fixed and flexible regimen whereas, later in the cycle, there is insufficient suppression in particular with the flexible mode of administration. The present review demonstrates that one has to account for ovarian function when studying the effect of LH suppression. Both women with a poor response and PCOS patients have a clearly disturbed ovarian function. In particular, anovulatory women with PCOS have completely different dynamics of follicular response to the combination of gonadotrophins with GnRH analogs (Scheele et al., 1993) . Also, in these women it is difficult to start the antagonist without any steroid pretreatment (a progestagen alone or in combination with an estrogen) because of the absence of an endogenous cycle.
Conclusion
Based on this systematic review, one could argue that in general with regard to effectiveness, i.e. ongoing pregnancy rates, the use of the long protocol agonist remains superior and could still be regarded as a potential first choice approach for prevention of premature luteinization, but this should be weighed against the moderately higher chance of developing OHSS.
In women with PCOS and poor responders, application of the GnRH antagonist as the first choice seems justified.
